Pad­cev, Keytru­da’s new sur­vival da­ta; Ser­ax­is rais­es $10M for di­a­betes cell ther­a­py

Pad­cev, Keytru­da’s con­fir­ma­to­ry win: Astel­las and Seagen said Fri­day that Pad­cev and Mer­ck’s Keytru­da helped cer­tain blad­der can­cer pa­tients live longer than chemother­a­py in a Phase III con­fir­ma­to­ry study. The com­bo treat­ment won ac­cel­er­at­ed ap­proval in April as a first op­tion for pa­tients who have blad­der can­cer that has spread to sur­round­ing or­gans or oth­er parts of the body and aren’t el­i­gi­ble for chemother­a­py. In the EV-302 study, which in­clud­ed pa­tients el­i­gi­ble for chemother­a­py, Pad­cev plus Keytru­da im­proved both over­all and pro­gres­sion-free sur­vival com­pared to chemo. The da­ta are set to sup­port an ap­pli­ca­tion for full US ap­proval in­clud­ing pa­tients el­i­gi­ble for chemother­a­py, which will be sub­mit­ted in the first quar­ter of next year, Seagen told End­points, as well as ex-US ap­provals. — Lei Lei Wu

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER